AstraZeneca
1,314
SEK
-3.31 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-3.31%
-11.22%
-14.45%
-9.16%
-18.18%
-20.17%
+1.86%
+29.89%
+7,089.95%
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.
Read moreMarket cap
2.04T SEK
Turnover
433.97M SEK
Revenue
596.39B
EBIT %
18.5 %
P/E
26.24
Dividend yield-%
2.6 %
Financial calendar
29/4
2025
Interim report Q1'25
All
Press releases
ShowingAll content types
AstraZeneca: Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer
Resultat för AstraZeneca: Q1 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools